Go to the profile of Amicoat

Amicoat

CEO, Amicoat

About Amicoat

Amicoat develops and commercializes groundbreaking antimicrobial technology based on nature's own defense mechanisms. Our focus is on antimicrobial agents that inhibit bacterial growth and the formation of biofilms. We offer a highly promising solution to the growing global antibiotic resistance epidemic. Our peptides, when in contact with bacteria, induce rapid bactericidal activity and nearly instantaneous bacterial cell death, before mechanisms of resistance can be conferred

Therapeutic Areas

Infectious

Technologies

Antimicrobial

Company Type

Medical technology

State of Ownership

Private

Sponsorship Group

Leader

Topics

Editions participated in:

June 2020